Premium
Comparison of the performance of two affinity depletion spin filters for quantitative proteomics of CSF: Evaluation of sensitivity and reproducibility of CSF analysis using GeLC‐MS/MS and spectral counting
Author(s) -
Fratantoni Silvina A.,
Piersma Sander R.,
Jimenez Connie R.
Publication year - 2010
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.200900179
Subject(s) - reproducibility , cerebrospinal fluid , proteomics , biomarker , proteome , biomarker discovery , chemistry , chromatography , medicine , biochemistry , gene
Purpose : For biomarker discovery in cerebrospinal fluid (CSF), removal of major serum proteins is advantageous as more CSF proteins including brain‐derived proteins can be identified. Our goal was to create a reproducible discovery workflow with acceptable throughput that can identify 500–1000 CSF proteins in small volumes of CSF. Experimental design : In this study, we compared the performance of two multi‐affinity depletion methods in spin filter format: MARS Human 14 and Seppro‐IgY‐14. To this end, we analyzed depleted and bound CSF fractions isolated from 0.5 mL aliquots of the same CSF sample ( n =3 per depletion method) by label‐free GeLC‐MS/MS‐based proteomics and normalized spectral counting. Results : The whole CSF dataset contained 884 proteins identified at high confidence. Depletion spin filter performance was assessed in terms of sensitivity and reproducibility of the CSF analysis. MARS and IgY‐14 spin filters yielded comparable reproducibility of protein identification (71–74%) and quantification (CV 17–18%) but a significant difference in the total number of identified CSF proteins (767 and 703 proteins, respectively). Conclusions and clinical relevance : The MARS filter compared to IgY‐14 filter provides a CSF analysis with enhanced proteome coverage. We anticipate that this enhanced sensitivity will facilitate biomarker discovery in early stages of cancer or neurological disease.